Strain Data Sheet

RBRC02285

Strain Information

Image
BRC No.RBRC02285
TypeTargeted Mutation and TransgeneCartagena
SpeciesMus musculus
Strain nameC57BL/6-St3gal4<tm1.1Bsi>
Former Common nameST34(#9 CAGCre)C57BL/6J:913 line, 913, C57BL/6-St3gal4<tm1.1Bsi> Tg(CAG-cre)913Bsi
H-2 Haplotype
ES Cell lineMS12 [C57BL/6]
Background strainC57BL/6JJcl
Appearanceblack [a/a B/B C/C]
Strain developmentDeveloped by Dr. Yoshio Hirabayashi, RIKEN BSI in 2004. St3gal4 null allele (St3gal4<tm1.1Bsi>) was generated by transient cre expression MS12 ES cells from St3gal4<tm1Bsi> that having a loxP flanked site in this allele.
Strain descriptionSt3gal4 (ST3GAL IV) knockout mouse. St3gal4 is one of alpha 2,3-sialyltransferases that is abundantly expressed in adult placenta, ovary, and testis.
Colony maintenanceBackcross to C57BL/6 (Heterozygote x C57BL/6JJcl))
References

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
St3gal4ST3 beta-galactoside alpha-2,3-sialyltransferase 49St3gal4targeted mutation 1.1, RIKEN BSI
loxPphage P1 loxP9loxP

Phenotype

Annotation by Mammalian phenotyhpe ontology
  • abnormal conditioned emotional response(MP:0002806)

  • abnormal insulin-like growth factor I level(MP:0008831)

  • abnormal sleep pattern(MP:0001501)

  • behavioral despair(MP:0002573)

  • decreased frequency of paradoxical sleep(MP:0012286)
    • more 5 phenotypes
  • decreased growth hormone level(MP:0005136)

  • decreased kindling response(MP:0001500)

  • increased anxiety-related response(MP:0001363)

  • increased coping response(MP:0003063)

  • increased fear-related response(MP:0003459)
    • Detailed phenotype data

    Ordering Information

    Donor DNAmouse ST3Gal IV genomic DNA, phage P1 loxP, CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA)
    Research applicationMetabolism Research
    Mouse Models for Human Disease
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers.
    2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSIOR/DEVELOPER. At the same time, the RECIPENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate.
    3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results.
    4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not requie collaboration, the RECIPIENT agrees to cite the literatire(s) designated by the DEPOSITOR/DEVEVLOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered.
    5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER.
    6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity.
    DepositorYoshio Hirabayashi (RIKEN)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. CAGGS MTA (English)
    5. Acceptance of responsibility for living modified organism (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    Srimontri P, Endo S, Sakamoto T, Nakayama Y, Kurosaka A, Itohara S, Hirabayashi Y, Kato K.
    Sialyltransferase ST3Gal IV deletion protects against temporal lobe epilepsy.
    J Neurochem 131(5) 675-87(2014) 25066807
    Fujita A, Okuno T, Oda M, Kato K.
    Urinary volatilome analysis in a mouse model of anxiety and depression.
    PLoS One 15(2) e0229269(2020) 32084196
    Kato K.
    Differential effects of dietary oils on emotional and cognitive behaviors.
    PLoS One 10(3) e0120753(2015) 25799588